Friday, July 10, 2026

Drug profile · INN

dasabuvir

dasabuvir (EXVIERA) is an FDA-listed pharmaceutical active ingredient.

EMA: withdrawn Antiinfectives for systemic use (J05) J05AP09
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dasabuvir
Class
Antiinfectives for systemic use (J05)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

dasabuvir (EXVIERA) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN dasabuvir
Brand EXVIERA
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AP09

Approval history

Authority Status Date
EMA withdrawn

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is dasabuvir?

dasabuvir (EXVIERA) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for dasabuvir?

EXVIERA is a marketed brand name for dasabuvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.